How Lupin’s Generic Xtandi® Could Shake Up the U.S. Oncology Market
Explore how Lupin’s tentative FDA approval of generic Xtandi® could reshape the prostate‑cancer market, boost patient access, and impact Astellas’ revenue.
4 minutes to read
ASTELLAS PHARMA INC.
How Astellas’ Legal Case and NMIBC Pipeline Shape Its Future
Explore how Astellas Pharma’s legal case reshapes compliance and fuels its promising NMIBC oncology pipeline, driving future growth and investor confidence.
4 minutes to read
2026 Astellas Pharma Dividend Outlook: 78 JPY/Share, Payouts, and Future Risks
Explore Astellas Pharma’s 2026 dividend outlook, financial strengths, and emerging risks in Japan’s pharma market.
5 minutes to read
How Astellas Pharma Navigates Japan’s 2026 Pharma Landscape & Patent Challenges
Japanese pharma faces price pressure and patent cliffs; Astellas can boost margins and growth by targeting high‑impact biologics, strategic M&A, and robust market‑access tactics.
4 minutes to read